Dear Doctor Letter (Rote-Hand-Brief) on Iclusig® (ponatinib): Updated information on the risk of vascular occlusion
2013.12.09
Active substance: ponatinib
Extension of warnings to include the risk of severe vascular occlusion associated with ponatinib.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN